Essential Thrombocythemia Archives - Oncology Nurse Advisor

Depression Common Among Patients With a Myeloproliferative Neoplasm

By

October 28, 2020

Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.

Myeloproliferative Neoplasms

Some Patients With AML Secondary to MPN May Benefit From Venetoclax in Combination With a Hypomethylating Agent

By

Susan Moench, PhD, PA-C

October 21, 2020

Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.

A clinician reviews a spinal radiograph.

Myeloproliferative Neoplasms

Bone Fracture Risk Increased in Patients With Myeloproliferative Neoplasms

By

Susan Moench, PhD, PA-C

October 7, 2020

Retrospective analysis sought to determine incidence of hip and vertebral fractures in patients with MPN compared with that of the general population.

Light micrograph of a blood smear from a patient with polycythemia vera.

Myeloproliferative Neoplasms

Interferon Alpha and Pegylated Interferon Alpha Can Be Safe, Effective for Treatment of Essential Thrombocythemia and Polycythemia Vera

By

Susan Moench, PhD, PA-C

October 5, 2020

Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.

Myeloproliferative Neoplasms

Assessment of Organ Elasticity as a Surrogate for Bone Marrow Fibrosis in Myeloproliferative Neoplasms

By

Susan Moench, PhD, PA-C

September 4, 2020

Spleen stiffness was found to be correlated with the extent of bone marrow fibrosis, as well as clinical outcome, in patients with MPNs.

Myeloproliferative Neoplasms

MPN Genomic Calculator Performs Well in Real-Life Cohort of Patients With Essential Thrombocythemia

By

Susan Moench, PhD, PA-C

July 29, 2020

The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.

Woman extracting a pill from the blister

Myeloproliferative Neoplasms

Cutaneous AEs Are Common in Patients With MPNs Treated With Hydroxyurea

By

Susan Moench, PhD, PA-C

July 27, 2020

Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.

A recent article is only the latest in a series of studies drawing attention to the importance of di

Myeloproliferative Neoplasms

High-Risk Mutations May Underlie Worse Outcomes in Men With MPN, Study Suggests

By

Susan Moench, PhD, PA-C

July 1, 2020

This study showed that MPN is more aggressive in men vs women and explored whether sex differences in the genomic landscape of MPN could explain this difference.

Platelet aggregation and platelet activation were both independently associated with bleeding risk.

Myeloproliferative Neoplasms

Evaluation of Real-World Experience With Long-Term Use of Anagrelide in the Setting of Essential Thrombocythemia

By

Susan Moench, PhD, PA-C

June 10, 2020

Anagrelide, a platelet-lowering agent with US FDA approval and EMA licensing for the treatment of patients with ET, is associated with prolonged response to initial therapy.

The novel drug appeared effective in healthy, previously untreated patients, but cost, side effects, and other issues may stand in the way of its widespread use.

Myeloproliferative Neoplasms

Acute Hospital Care Drives Healthcare Expenditures in Patients With MPN, Study Finds

By

Susan Moench, PhD, PA-C

May 29, 2020

An additional notable finding from this study was that the absence of specialist care was associated with higher healthcare costs among patients with MPNs.